Polycystic Ovary Syndrome. Sclerocystic ovary syndrome Stein-Leventhal syndrome
Conditions
Interventions
Intervention 1: to the intervention group Quercetin supplements , 1 g daily for 12 weeks as the two tablets of 500 mg after 2 main meals (breakfast and lunch)and should not be taken on an empty stomac
Treatment - Drugs
Placebo
to the intervention group Quercetin supplements , 1 g daily for 12 weeks as the two tablets of 500 mg after 2 main meals (breakfast and lunch)and should not be taken on an empty stomach.
Patients in the placebo group will receive 12 weeks of placebo quercetin
Sponsors
Tehran University of Medical Sciences
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: BMI 25 to 40 - the age range of 20-40 years - according to the Rotterdam conference, at least two of the three criteria listed as having the disease. Features include menstrual irregularities, or clinical symptoms and the presence of polycystic ovaries on ultrasound – Hyperandrogenism. donot use drugs; contraceptive drugs, antihypertensive drugs lower blood lipid and anti-inflammatory drug- and willing to cooperate. Exclusion criteria: Endocrine and metabolic diseases such as hypothyroidism and hyperthyroidism, androgen producing cancer, diabetes mellitus, adrenal hyperplasia and Cushing, ovarian tumor and Hyperprolactinaemia - Smoking - Pregnancy - allergic reaction to supplements - Cancel patient to cooperate in the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum adiponectin. Timepoint: Before and after intervention. Method of measurement: Adiponectin ELISA Kit µg / ml. | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor necrosis factor. Timepoint: Before and after intervention. Method of measurement: Serum concentrations of TNFa ELISA kit.;C-reactive protein. Timepoint: Before and after intervention. Method of measurement: Serum levels of hs-CRP ELISA Kit.;High-molecular weight adiponectin levels. Timepoint: Before and after intervention. Method of measurement: Adiponectin ELISA Kit µg / ml.;Glucose. Timepoint: Before and after intervention. Method of measurement: Serum ELISA Kit.;Insulin. Timepoint: Before and after intervention. Method of measurement: Serum ELISA kit micro mol / l.;Adenosine monophosphate-activated protein kinase. Timepoint: Before and after intervention. Method of measurement: Serum ELISA Kit.;Adiponectin receptor 1. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Adiponectin receptor 2. Timepoint: Before and after intervention. Method of measurement: RT-PCR.;Testosterone. Timepoint: Before and after intervention. Method of measurement: Serum Elisa kit.;Progesterone. Timepoint: Before and after intervention. Method of measurement: serum Elisa kit.;Luteinizing hormone. Timepoint: Before and after intervention. Method of measurement: ELISA kit.;Follicle stimulating hormone. Timepoint: Before and after intervention. Method of measurement: ELISA kit.;Sex Hormone Binding Globulin. Timepoint: Before and after intervention. Method of measurement: IRMA.;Systolic blood pressure. Timepoint: Before and after intervention. Method of measurement: Pressure set.;Diastolic blood pressure. Timepoint: Before and after intervention. Method of measurement: Pressure set.;Total cholesterol. Timepoint: Before and after intervention. Method of measurement: Serum total cholesterol concentration turbidometry mg / dl.;Triglyceride. Timepoint: Before and after intervention. Method of measurement: Serum triglyceride concentrations were enzymatically mg / dl.;Low-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: LDL-C levels | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNeda Rezvan
Tehran University of Medical Sciences
Outcome results
None listed